Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01319331 · ClinicalTrials.gov registry record · Phase 1
The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01319331 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 12 participants.
The verdict
NCT01319331, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the drug Alpha-1 Antitrypsin (AAT, Aralast NP) will preserve beta-cell function and help slow the progression of type 1 diabetes.
Interventions
- DRUG Alpha 1-Antitrypsin (AAT, Aralast NP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01319331
The ClinicalTrials.gov registry entry for NCT01319331 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alpha 1-Antitrypsin (AAT, Aralast NP) is the first listed.
NCT01319331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01319331 about?
NCT01319331 is a clinical study titled "The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes". The purpose of this study is to determine if the drug Alpha-1 Antitrypsin (AAT, Aralast NP) will preserve beta-cell function and help slow the progression of type 1 diabetes.
What is the current status of trial NCT01319331?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-10. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01319331?
The interventions under investigation include: Alpha 1-Antitrypsin (AAT, Aralast NP) (DRUG).
Who is sponsoring clinical trial NCT01319331?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.